Beta Bionics CFO exercises options, sells 382 shares

Q: How many BBNX options did Stephen Feider exercise?

Stephen Feider exercised 382 employee stock options on November 5, 2026, at an exercise price of $5.10 per share, acquiring 382 common shares.

Q: How many BBNX shares did Stephen Feider sell, and at what price?

Stephen Feider sold 382 common shares on November 5, 2026, at a weighted average price of $17.036649 per share. The sale was pursuant to a Rule 10b5-1 plan adopted on July 31, 2026; the reported price range was $17.00 to $17.07 per share.

Q: How do the BBNX options reported by Stephen Feider vest?

The shares subject to the option vest in 48 equal monthly installments measured from September 14, 2023.

The chief financial officer held 39,313 options after the reported exercise.

Available on EDGAR 11/09/2026 - 04:26 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:26 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) Chief Financial Officer Stephen Feider exercised 382 employee stock options at a $5.10 exercise price on November 5, 2026, acquiring 382 common shares and selling 382 common shares that day at a weighted average $17.036649 per share. The sale was pursuant to a Rule 10b5-1 plan adopted on July 31, 2026; 39,313 options were held directly after the exercise.

Insider Trade Summary 10b5-1

Exercise and Sale: 382 shares ($5K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Feider Stephen

Role Chief Financial Officer

Sold 382 shs ($7K)

Approx. gross sale proceeds $7K

Approx. exercise cost $2K

Approx. pre-tax spread $5K

Share of Position Sold 0.24%

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) ^F3	382	$0.00	$0.00
Exercise	Common Stock	382	$5.10	$2K
Sale	Common Stock ^{F1, F2}	382	$17.0366	$7K

Holdings After Transaction: Employee Stock Option (right to buy) — 39,313 options (Direct); Common Stock — 159,378 shares (Direct)

Holdings Before and After: Employee Stock Option (right to buy), 39,695 to 39,313 options (Direct); Common Stock, 159,378 to 159,378 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2026.
F2. The weighted average sale price for the transaction reported was $17.036649 and the range of prices were between $17.00 and $17.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Key Figures

Employee stock options exercised: 382 options Exercise price: $5.10 per share Common shares acquired: 382 shares +4 more

7 metrics

Employee stock options exercised 382 options November 5, 2026

Exercise price $5.10 per share Options exercised November 5, 2026

Common shares acquired 382 shares On exercise, November 5, 2026

Common shares sold 382 shares November 5, 2026

Weighted average sale price $17.036649 per share Sale on November 5, 2026

Sale price range $17.00 to $17.07 per share Shares sold November 5, 2026

Options held after exercise 39,313 options Direct holdings following the November 5, 2026 transaction

Key Terms

Employee Stock Option (right to buy), Rule 10b5-1 Plan, weighted average sale price, vest

4 terms

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

Rule 10b5-1 Plan regulatory

"sold pursuant to a Rule 10b5-1 Plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The weighted average sale price for the transaction reported"

vest technical

"shares subject to this option shall vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBNX options did Stephen Feider exercise?

Stephen Feider exercised 382 employee stock options on November 5, 2026, at an exercise price of $5.10 per share, acquiring 382 common shares.

How many BBNX shares did Stephen Feider sell, and at what price?

Stephen Feider sold 382 common shares on November 5, 2026, at a weighted average price of $17.036649 per share. The sale was pursuant to a Rule 10b5-1 plan adopted on July 31, 2026; the reported price range was $17.00 to $17.07 per share.

How do the BBNX options reported by Stephen Feider vest?

The shares subject to the option vest in 48 equal monthly installments measured from September 14, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last)

(First)

(Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE

CALIFORNIA

92618

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/05/2026		M		382	A	$5.1	159,760	D
Common Stock	11/05/2026		S⁽¹⁾		382	D	$17.0366⁽²⁾	159,378	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$5.1	11/05/2026		M			382	⁽³⁾	09/13/2033	Common Stock	382	$0.00	39,313	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2026.

2. The weighted average sale price for the transaction reported was $17.036649 and the range of prices were between $17.00 and $17.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Remarks:

	/s/ Thomas Sohn, Attorney-in-Fact	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR